Discover
TRML
Tourmaline Bio, Inc.
47.98
undefined x undefined
undefined x undefined
bid
ask
+
0.00
0.00%
04:00 PM
| Ytd | 136.59% | |
| 1y | 80.44% |
47.98
day range
47.98
11.56
52 week range
48.27
| Open | 47.98 | Prev Close | 47.98 | Low | 47.98 | High | 47.98 | Mkt Cap | 1.23B |
| Vol | 779.87K | Avg Vol | 1.01M | EPS | -3.44 | P/E | N/A | Forward P/E | -13.18 |
| Beta | 1.58 | Short Ratio | 1.12 | Inst. Own | 89.13% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | N/A | 50-d Avg | 42.23 | 200-d Avg | 23.14 | 1yr Est | 48.00 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2025-11-06 | 2025-09 | 0 | N/A | N/A | N/A |
| 2025-08-13 | 2025-06 | 0 | N/A | N/A | N/A |
| 2025-05-02 | 2025-03 | 0 | N/A | N/A | N/A |
| 2025-03-13 | 2024-12 | 0 | N/A | N/A | N/A |
| 2024-11-07 | 2024-09 | 0 | N/A | N/A | N/A |
| 2024-08-08 | 2024-06 | 0 | N/A | N/A | N/A |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2025-09-15 | BMO Capital | Downgrade | Outperform | Market Perform |
| 2025-09-11 | Piper Sandler | Downgrade | Overweight | Neutral |
| 2025-09-10 | Truist Securities | Downgrade | Buy | Hold |
| 2025-09-10 | Guggenheim | Downgrade | Buy | Neutral |
| 2025-09-10 | HC Wainwright & Co. | Downgrade | Buy | Neutral |
| 2025-09-10 | Chardan Capital | Downgrade | Buy | Neutral |
Profile
Tourmaline Bio, Inc. operates as a clinical biotechnology company that develops medicines for patients with life-altering immune and inflammatory diseases. It develops TOUR006, a human anti-IL-6 monoclonal antibody that selectively binds to interleukin-6, a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. The company's development pipeline comprises medicines and therapies for the atherosclerotic cardiovascular disease (ASCVD) and thyroid eye disease (TED). The company was formerly known as Tourmaline Bio, LLC and changed its name to Tourmaline Bio, Inc. in September 2022. Tourmaline Bio, Inc. was founded in 2021 and is headquartered in New York, New York. Tourmaline Bio, Inc. operates as a subsidiary of Novartis AG.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2025-10-14 | CASTELEIN CALEY M. | Director | 947.94K | Stock Gift |
| 2025-10-14 | JOHNSON KEVIN BRUCE | Officer | 51.58K | Stock Gift |
| 2025-10-23 | KANTOFF AARON | Director | 88.28K | Stock Gift |
| 2025-10-21 | KULKARNI SANDEEP CHIDAMBAR | Chief Executive Officer | 762.05K | Conversion of Exercise of derivative security |
| 2024-01-28 | MCDADE MARK D. | Director | 0.00 | Purchase |
| 2025-10-21 | ROBINSON RYAN F. | Chief Financial Officer | 14.37K | Conversion of Exercise of derivative security |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2025-06-29 | Avoro Capital Advisors LLC | 2.56M | 122.62M | 9.95% |
| 2025-06-29 | RA Capital Management, L.P. | 2.54M | 121.82M | 9.88% |
| 2025-06-29 | QVT Financial LP | 2.15M | 103.38M | 8.39% |
| 2025-06-29 | Blackrock Inc. | 1.63M | 78.40M | 6.36% |
| 2025-06-29 | TCG Crossover Management, LLC | 1.48M | 70.89M | 5.75% |
| 2025-06-29 | Pfizer Inc | 1.27M | 61.04M | 4.95% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2025-06-29 | VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 740.61K | 35.53M | 2.88% |
| 2025-09-29 | iShares Trust-iShares Russell 2000 ETF | 430.74K | 20.67M | 1.68% |
| 2025-06-29 | VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 293.85K | 14.10M | 1.14% |
| 2025-08-30 | Fidelity Salem Street Trust-Fidelity Small Cap Index Fund | 191.80K | 9.20M | 0.75% |
| 2025-09-29 | iShares Trust-iShares Russell 2000 Value ETF | 153.29K | 7.35M | 0.60% |
| 2025-08-30 | Fidelity Concord Street Trust-Fidelity Extended Market Index Fund | 100.97K | 4.84M | 0.39% |
Dividend
| Dividend | Date |
|---|---|
| 1.5118 | 2023-10-20 |